Evotec: End-to-End Partner to Big Pharma
Former EVP at Evotec
inpractise.com/articles/evotec-end-to-end-partner-to-big-pharma
Former EVP at Evotec
The executive has over 30 years experience in the Life Sciences industry. The executive spent over a decade with GSK and Evotec, leading their Drug Discovery efforts.
Interview Transcript
This is a snippet of the transcript, sign up to read more.
Evotec often discusses "innovate" and "execute" as two separate platforms. Is that the distinction you're referring to, where "innovate" involves working with partners to develop assets for commercial markets, and "execute" is more about fee-for-service relationships?
This adds value to the collaboration. Typically, it would be based on a large upfront research payment to cover the research costs that Evotec can manage flexibly in collaboration with the partner. Essentially, Evotec's role is to help BMS build a portfolio in the neuroscience area, because BMS doesn't have internal neuroscience research. They have very experienced people with a lot of background, but they don't have labs in that area. So they work with Evotec's joint project teams to manage those budgets, manage those projects, and make decisions. Hopefully, this will result in INDs and products that will move forward into the market.
This is a snippet of the transcript, sign up to read more.
I'm curious, what makes panomics, as implemented by Evotec, unique? How does Evotec differentiate their approach to panomics from the industry's usage of the term to attract partners and customers?
Evotec is now focusing on building proprietary molecular patient databases in certain disease areas. They are collecting high-quality clinical data from very homogeneous sets of patients over time, in a carefully curated way. For instance, in the kidney disease space, they have data from over 10,000 patients. These samples are then sequenced, producing a massive amount of data.
This is a snippet of the transcript, sign up to read more.
I'm curious, what makes panomics, as implemented by Evotec, unique? How does Evotec differentiate their approach to panomics from the industry's usage of the term to attract partners and customers?
This data is key to deconvoluting human disease pathways. Evotec's precision medicine platform is based on human disease and comes directly from patients with the disease. This approach has a direct genetic link to human disease, unlike traditional approaches to drug discovery that relied on unpredictable animal models.
This is a snippet of the transcript, sign up to read more.
Related Content
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.